Have received many emails, Friends, asking why 5 Underwriters, why not a loan that is better for shareholders rather than adding shares that dilute shareholder/owner value. Simple, arna couldn't afford a loan with it's weighted avg cost of capital at 13.55% which is 9.3 points higher than prime. Especially w/it's Return on Capital of - 618.32%. Only option is dilution. Needed 5 Banks to run it cause underwriting arna is too risky for 1,2,3 or 4. Underwriters needed to spread risk. Well, Tues July 25th 2017 had 70.1% of trades shorting arna. Ouch!. Don't trust pumpers, they lie, distort and mislead. Check for ticks. Stay tuned and Cheers!!
When the 5 Underwriter Banks shut down their support algos pps will fall like a rock.
ARNA longs and pumpers rejoice in 20 years of unprofitability. Give high fives on having just 1 approved drug, a very poor selling diet pill, in 20 years. Dance about dilutions being life source. Raise their arms in the air rejoicing in their losses as only insiders make millions. Hallelujah!
Aww...PPS Up a WHOPPING .002 cents!! Whopper Flippers Pretend Reverse Split Never Happened. WOO HOO! Sharing OREO Flurries Believing the 5 Banksters ARE NOT doing all they can to KEEP PPS THIS HIGH . Whopper Flippers WHOOPING happy about ATM Dilution starting in JAN, getting DILUTED 24% in APRIL, HAVING Shares 1:10 RS in JUNE then DILUTED again in JULY. WOO HOO!!
Friends, well pps went up 0.029 pennies on Monday July 24, 2017 taking into account the recent 1:10 Reverse Split. Longs seem angry and disappointed as the well should with all the lies and distortions pumpers and promoters feed them. On Monday 67.3% of trades shorted Arna. Don't trust pumpers. Remember so-called pipe is old, tiny, delayed and unwanted. If you go out of doors check for ticks. They're nasty disease carriers. Stay tuned. Cheers!
A couple of more items about ancient Etrasimod. The EPRSQ guy who leads ARNA now and flooded our beloved company with EPRSQ peeps goofed up by getting rid of top scientists and Dominic. That has really critically slowed apd334 progress almost to the point that it's doom is practically guaranteed. Our company has filed with SEC numerous times indicating that other patents will jeopardize commercialization of Etrasimod. Besides CELG, other BP"S have gone past this old, delayed research drug. Just today LLY partnered for a sum of $400M with a basically preclinical drug from NKTR for autoimmune diseases of IBD and others.
Gang of 5 Banksters having hard time getting rid of shares. PPS just hovering at offering price. Bad news, but expected. Wise investors know junk can't be hidden by smoke and mirrors.
AWW...Up a WHOPPING .001 cents! WHOPPER FLIPPERS splitting OREO Flurry's to celebrate.
big name backers: AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly, Johnson & Johnson Innovation, Watson Fund, WRF Capital and WuXi AppTec help start-up Rodeo Therapeutics that's working on ulcerative colitis and other diseases. AbbVie, Lilly and JNJ ignore arna for UC.
PPS up on 200 shares. Looks like low volume pre-market pps manipulation to trick you to buy. 5 Underwriters playing share ping pong to jack the pps as they try to unload their discounted shares. No reason to buy. Anything you buy can and will be used against you. Diluted Trapped Longs have no chance of re-couping losses. 3 dilutions and RS in seven months. Don't fall for underwriter tricks. Dyodd
Friends, you'd be well advised to not put any stock in the pumper noise of buyout or acquiring pipeline pieces or whole. For those newbies this buyout ploy has been used for over a decade by criminal pumpers. There's no value to the pipe. BP has checked it and passed. On Thurs July 20th 37.5% of trades went short and on Fri July 21 40.3% of trades shorted. Count on pps falling soon as the 5 Investment Bank Underwriters start ending their support that's keeping pps artificially high. Remember don't trust pumpers or desperate underwater longs. Check for ticks if you go outdoors. Stay tuned. Cheers!!
KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”
Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.
Lilly joins other BP's in skipping ARNA for Autoimmune diseases like UC, Crohns and others. Partners with Nektar Therapeutics Phase 1 autoimmune research drug. BP has no interest in ARNA's old, delayed, pipe. Arna can't compete.
Looks like the 5 Underwriters are doing low volume shenanigans with pps to trick you to buy. Don't fall for underwriter tricks. Arna not worth $1.50 let alone the Reverse Split pps at now. Anything you buy can and will be used against you. DYODD
Looks like low volume pre-market pps manipulation to trick you to buy. 5 Underwriters playing share ping pong to jack the pps as they unload their discounted shares Up on 220 shares. No reason to buy. Anything you buy can and will be used against you. Diluted Trapped Longs have no chance of re-couping losses. 3 dilutions and RS in seven months. Don't fall for underwriter tricks. Dyodd
Unless and Until they get rid of half the BOD and half the upper management Longs are doomed.
Lots of pleasure is found in watching the longs on this board make complete jerks of themselves. Even with 5 Underwriting Investment banks intervening with pps using fake price targets, share games, fake loss projections the pps is up 90 cents ( taken into account the 1:10 reverse split) since the reverse split. Longs are underwater still. So even with all the help of 5 banksters fighting hard the market knows this is junk and is standing strong in the face of blatant manipulation. When the banksters contracts expire pps will tank to where it rightfully belongs.
Longs like to pepper this board with crazy delusions and lies. They look at 1 month after the RS as a reason to be joyful and pretend pps hasn't gone down due to factors of this 20 year old company with only a poor selling diet pill. They ignore fact of 5 Investment bank agents supporting pps. They are keeping pps artificially high to dump their discounted Underwritten and greenshoe shares. These Underwriters are even now saying losses will be less. Again they have shares to dump. PPS will go lower as the investment banks leave .PUMPERS HAVE BEEN EXPOSED and EXUBERANCE OF LONGS BUILT ON NOTHING BUT INVESTMENT BANK GAMES WILL LEAD TO MOANING.
THEY ARE DESPERATELY TRYING TO KEEP THE PRICE CLOSE TO THE OFFERING BUT THEY WILL FAIL...HISTORY TELLS US THIS SCAM COMPANY HAS SCAMMED THEIR INVESTORS ONCE MORE FOR THE UMTEENTH TIME...AS USUAL MANAGEMENT GOT THE MONEY AND SHAREHOLDERS GOT SCREWED...dyodd
Axon pps down since presented Nelotanserin Data at Alzheimer's Association International Conference. That's bad for Arna.